{"id":"https://openalex.org/W4362545294","doi":"https://doi.org/10.1158/1940-6207.c.6547403","title":"Data from Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP)","display_name":"Data from Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP)","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362545294","doi":"https://doi.org/10.1158/1940-6207.c.6547403"},"language":"en","primary_location":{"id":"doi:10.1158/1940-6207.c.6547403","doi":"https://doi.org/10.1158/1940-6207.c.6547403","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1940-6207.c.6547403","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1940-6207.c.6547403","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5104256392","display_name":"Ahmet M. Ulusan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ahmet M. Ulusan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077577650","display_name":"Praveen Rajendran","orcid":"https://orcid.org/0000-0002-6221-7366","observed_orcids":["https://orcid.org/0000-0002-6221-7366"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Praveen Rajendran","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108966588","display_name":"Wan Mohaiza Dashwood","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wan Mohaiza Dashwood","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0351-4034","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004683483","display_name":"Omer F. Yavuz","orcid":"https://orcid.org/0000-0002-7366-2772","observed_orcids":["https://orcid.org/0000-0002-7366-2772"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Omer F. Yavuz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020639999","display_name":"Sabeeta Kapoor","orcid":"https://orcid.org/0000-0001-7906-3343","observed_orcids":["https://orcid.org/0000-0001-7906-3343"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sabeeta Kapoor","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7906-3343","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037351988","display_name":"Trace A. Gustafson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Trace A. Gustafson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028539956","display_name":"Michelle I. Savage","orcid":"https://orcid.org/0000-0003-4927-9471","observed_orcids":["https://orcid.org/0000-0003-4927-9471"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michelle I. Savage","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069756775","display_name":"Powel H. Brown","orcid":"https://orcid.org/0000-0002-3398-163X","observed_orcids":["https://orcid.org/0000-0002-3398-163X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Powel H. Brown","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3398-163X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062384041","display_name":"Shizuko Sei","orcid":"https://orcid.org/0000-0002-4822-6602","observed_orcids":["https://orcid.org/0000-0002-4822-6602"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shizuko Sei","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043464019","display_name":"Altaf Mohammed","orcid":"https://orcid.org/0000-0003-1058-6909","observed_orcids":["https://orcid.org/0000-0003-1058-6909"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Altaf Mohammed","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057373704","display_name":"Eduardo Vilar","orcid":"https://orcid.org/0000-0001-6404-3761","observed_orcids":["https://orcid.org/0000-0001-6404-3761","https://orcid.org/0000-0001-6628-0787"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eduardo Vilar","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6404-3761","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5082820494","display_name":"Roderick H. Dashwood","orcid":"https://orcid.org/0000-0003-0351-4034","observed_orcids":["https://orcid.org/0000-0003-0351-4034"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roderick H. Dashwood","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0351-4034","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11369","display_name":"Genetic factors in colorectal cancer","score":0.5770999789237976,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11369","display_name":"Genetic factors in colorectal cancer","score":0.5770999789237976,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.2736999988555908,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.0722000002861023,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9300000071525574},{"id":"https://openalex.org/keywords/sulindac","display_name":"sulindac","score":1.0},{"id":"https://openalex.org/keywords/familial-adenomatous-polyposis","display_name":"familial adenomatous polyposis","score":0.9909999966621399},{"id":"https://openalex.org/keywords/dosing-regimen-optimization","display_name":"dosing regimen optimization","score":0.871999979019165},{"id":"https://openalex.org/keywords/adenomatous-polyps","display_name":"adenomatous polyps","score":0.7609999775886536},{"id":"https://openalex.org/keywords/erk1-2-phosphorylation","display_name":"ERK1/2 phosphorylation","score":0.7319999933242798},{"id":"https://openalex.org/keywords/matrix-metalloproteinase-7","display_name":"matrix metalloproteinase-7","score":0.9580000042915344},{"id":"https://openalex.org/keywords/tnf-alpha","display_name":"TNF-\u03b1","score":0.9980000257492065},{"id":"https://openalex.org/keywords/early-growth-response-1","display_name":"early growth response 1","score":0.9419999718666077},{"id":"https://openalex.org/keywords/colectomy","display_name":"colectomy","score":0.6510000228881836},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.36399999260902405}],"concepts":[{"id":"https://openalex.org/C2776241388","wikidata":"https://www.wikidata.org/wiki/Q963093","display_name":"Sulindac","level":3,"score":0.8169232606887817},{"id":"https://openalex.org/C2780814781","wikidata":"https://www.wikidata.org/wiki/Q1369011","display_name":"Familial adenomatous polyposis","level":4,"score":0.7456567287445068},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.6737826466560364},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6511122584342957},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.5730613470077515},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5572468042373657},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.45684587955474854},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4377850294113159},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3820558786392212},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.33905184268951416},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.12180519104003906},{"id":"https://openalex.org/C2778484676","wikidata":"https://www.wikidata.org/wiki/Q20707196","display_name":"Nonsteroidal","level":2,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1940-6207.c.6547403","doi":"https://doi.org/10.1158/1940-6207.c.6547403","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1940-6207.c.6547403","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1940-6207.c.6547403.v1","doi":"https://doi.org/10.1158/1940-6207.c.6547403.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1940-6207.c.6547403.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1940-6207.c.6547403","doi":"https://doi.org/10.1158/1940-6207.c.6547403","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1940-6207.c.6547403","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3107260053","https://openalex.org/W3210162854","https://openalex.org/W3083317297","https://openalex.org/W2953888268","https://openalex.org/W4282968323","https://openalex.org/W4393086629","https://openalex.org/W2789271913","https://openalex.org/W4362634976","https://openalex.org/W3210382520","https://openalex.org/W2304625472"],"abstract_inverted_index":{"Abstract":[0],"A":[1,105],"clinical":[2,233,280],"trial":[3],"in":[4,20,38,41,50,82,88,112,164,227,273],"patients":[5,236,283],"with":[6,126,221,232,237,267,279,284],"familial":[7],"adenomatous":[8,225,271],"polyposis":[9,40],"(FAP)":[10],"demonstrated":[11,109],"that":[12,202,248],"sulindac":[13,269],"plus":[14,91,186],"erlotinib":[15],"(SUL+ERL)":[16],"had":[17],"good":[18,219,265],"efficacy":[19,111,220,266],"the":[21,39,89,113,165,174,177,213,228,259,274],"duodenum":[22],"and":[23,73,115,147,160,170,195,230,276],"colon,":[24],"but":[25],"toxicity":[26],"issues":[27],"raised":[28],"concerns":[29],"for":[30,53,168,235,282],"long-term":[31,106,166],"prevention.":[32],"We":[33,200],"performed":[34],"a":[35,63],"biomarker":[36],"study":[37,65,107,167],"rat":[42],"colon":[43,51,72,114,229,275],"(Pirc)":[44],"model,":[45],"observing":[46],"phosphorylated":[47],"Erk":[48],"inhibition":[49],"polyps":[52,226,272],"up":[54],"to":[55,206,252],"10":[56,183],"days":[57],"after":[58,241,288],"discontinuing":[59],"ERL+SUL":[60],"administration.":[61],"In":[62],"follow-up":[64],"lasting":[66],"16":[67,156],"weeks,":[68,119],"significant":[69],"reduction":[70],"of":[71,95,130,181,212,258],"small":[74,277],"intestine":[75],"(SI)":[76],"tumor":[77,143],"burden":[78],"was":[79,124,162],"detected,":[80],"especially":[81],"rats":[83],"given":[84,209,255],"250":[85,121,187],"ppm":[86,122,188],"SUL":[87,123,189,223],"diet":[90],"once-a-week":[92,127],"intragastric":[93,128],"dosing":[94],"ERL":[96,131,182],"at":[97,117,132,155,210,256],"21":[98],"or":[99,135,240,287],"42":[100,136],"mg/kg":[101,137,184],"body":[102],"weight":[103],"(BW).":[104],"further":[108],"antitumor":[110,198],"SI":[116],"52":[118],"when":[120],"combined":[125],"administration":[129],"10,":[133],"21,":[134],"BW.":[138],"Tumor-associated":[139],"matrix":[140],"metalloproteinase-7":[141],"(Mmp7),":[142],"necrosis":[144],"factor":[145],"(Tnf),":[146],"early":[148],"growth":[149],"response":[150],"1":[151],"(Egr1)":[152],"were":[153],"decreased":[154],"weeks":[157],"by":[158],"ERL+SUL,":[159],"this":[161],"sustained":[163],"Mmp7":[169],"Tnf.":[171],"Based":[172],"on":[173],"collective":[175],"results,":[176],"optimal":[178],"dose":[179],"combination":[180],"BW":[185],"lacked":[190],"toxicity,":[191],"inhibited":[192],"molecular":[193],"biomarkers,":[194],"exhibited":[196],"effective":[197],"activity.":[199],"conclude":[201],"switching":[203,249],"from":[204,250],"continuous":[205,251],"once-per-week":[207,253],"ERL,":[208],"one-quarter":[211,257],"current":[214,260],"therapeutic":[215,261],"dose,":[216,262],"will":[217,263],"exert":[218,264],"standard-of-care":[222,268],"against":[224,270],"SI,":[231],"relevance":[234,281],"FAP":[238,285],"before":[239,286],"colectomy.":[242,289],"Prevention":[243],"Relevance:":[244],"This":[245],"investigation":[246],"concludes":[247],"erlotinib,":[254],"intestine,":[278]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-06T00:00:00"}